# Alzheimer's Breakthroughs: Fresh Strategies and Insights

Newsy: Alzheimer’s News Weekly
Published: 2026-07-13T13:30:00.208Z
Source: https://newsyai.com/edition/ba41e911-1e20-41e3-a496-2c7a276b8a00
Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md

---

**Alzheimer’s Treatment Briefing: Fresh Angles on Blood Flow, Combo Therapies, and Early Drug Candidates**

**Coverage period: ~July 7–13, 2026**

Broad searches across recent sources, including research announcements, trial updates, and news outlets, identified a few meaningful new developments in Alzheimer’s treatment over the past seven days. The field continues its steady pace ahead of or during major conferences like AAIC 2026, with emphasis on supportive approaches and early-stage innovations rather than large-scale drug approvals.[[1]](https://health.yahoo.com/conditions/neurological/alzheimers-disease/articles/clinical-trial-shows-promise-first-154220427.html)

Below are the most relevant fresh insights, ranked by potential long-term impact on treatment strategies.

**1. Non-drug device shows promise for preserving memory by improving brain blood flow**  
**Overview**  
A randomized controlled trial of Cerezen—a non-invasive device designed to boost blood flow to the brain—found it helped maintain memory and daily independence in people with early Alzheimer’s. Benefits lasted even six months after the treatment period ended. Results appeared in the *American Journal of Alzheimer’s Disease & Other Dementias* around July 10, 2026.[[1]](https://health.yahoo.com/conditions/neurological/alzheimers-disease/articles/clinical-trial-shows-promise-first-154220427.html)

**Why this matters**  
Think of the brain as a garden that needs steady watering to stay healthy. When blood flow slows, harmful changes can take root faster. This device acts like a gentle, reliable irrigation system—supporting the brain’s natural resilience without drugs. It offers a practical, low-risk option that could complement existing therapies and highlights how addressing circulation might slow the disease’s course right now.

**2. New drug candidate KCL-286 reduces multiple Alzheimer’s-related problems in early lab tests**  
**Overview**  
Researchers at King’s College London tested KCL-286, an oral compound already shown safe in initial human studies (Phase 1), in mice modeling Alzheimer’s. It lowered DNA damage in brain cells, reduced inflammation, and eased other harmful processes. Findings were published in *FEBS Open Bio* around July 8–9, 2026.[[2]](https://www.insideprecisionmedicine.com/topics/translational-research/drug-candidate-shows-early-promise-for-treating-alzheimers-damage/)

**Why this matters**  
Alzheimer’s often involves several overlapping issues—like tangled proteins, inflammation, and cell stress—much like a storm with multiple fronts. This compound tackles several at once in early testing and has already cleared basic human safety checks while reaching the brain. It represents an emerging multi-target strategy that could lead to more comprehensive future treatments, though human trials for Alzheimer’s are still needed.

**3. UCSF launches early trial testing two therapies together against Alzheimer’s proteins**  
**Overview**  
University of California, San Francisco (UCSF) began screening participants for one of the first trials combining approaches to target both amyloid and tau proteins simultaneously in early or at-risk stages. Initial dosing with donanemab (an approved plaque-clearing drug) alongside another agent is underway. Announcements appeared around July 10–12, 2026.[[3]](https://www.eurekalert.org/news-releases/1135490)

**Why this matters**  
Current treatments often focus on one problem at a time, like clearing one type of clutter from a busy room. This trial explores whether addressing two key issues together works better before symptoms become severe. It could open doors to more effective prevention-style strategies and reflects growing interest in combination approaches as the field evolves.

No other major new trial readouts, mechanistic breakthroughs, or large-scale results emerged in this window. Ongoing work on approved therapies, blood tests, and lifestyle factors continues from prior periods.

## What this means for care right now
- These updates reinforce practical steps: discuss approved treatments and monitoring with your doctor, prioritize heart and vascular health (including blood flow support), and consider trial participation for access to emerging options.
- Tools for finding studies remain valuable.
- Watch for further data from conferences like AAIC.

## Sources
- Cerezen trial coverage and results (July 10, 2026).[[1]](https://health.yahoo.com/conditions/neurological/alzheimers-disease/articles/clinical-trial-shows-promise-first-154220427.html)
- KCL-286 preclinical study (July 8–9, 2026).[[2]](https://www.insideprecisionmedicine.com/topics/translational-research/drug-candidate-shows-early-promise-for-treating-alzheimers-damage/)
- UCSF combo trial launch announcements (July 10–12, 2026).[[3]](https://www.eurekalert.org/news-releases/1135490)

New supportive and early-stage insights continue to expand options while the broader pipeline advances.
